Vertex Pharma (VRTX): Reducing Estimates But See Upside To Lower Expectations - Jefferies
Get Alerts VRTX Hot Sheet
Rating Summary:
29 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 1
Join SI Premium – FREE
Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) but cut his price target to $104 from $107 on recent commentary regarding Rx refill lags leading the company to formally reduce its '16 Orkambi guidance.
The Orkambi slowdown adds to concerns about perceived benefit/risk and increases dependence on '661 and the 3x combo. However, the analyst is confident that VRTX will grow the opportunity with these future offerings. Orkambi's 6-11yo CF approval, while widely expected, does at least opens door for some add'l Orkambi growth beyond 3Q.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $88.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Hannover Rueck SE (HNR1:GR) (HVRRF) to Reduce
- Sinopharm Group Co Ltd. (1099:HK) (SHTDF) PT Lowered to HK$23 at HSBC
- Morgan Stanley Upgrades Vornado Realty Trust (VNO) to Equalweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!